Achilles Therapeutics ADRs Rise 32% on Cost-Cutting Measures

By MarketWatch | Sep 19, 2024 at 10:43 AM EST

Achilles Therapeutics' American depositary receipts surged 32% after announcing cost-cutting measures. The company plans to refocus its strategy and explore collaborations with third parties for cancer treatments. They also hired BofA Securities as a financial adviser for value-maximizing strategies.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.